General Inception

Enable Medicine is a biotechnology company founded in 2019 by Aaron Mayer and Sunil Bodapati in Menlo Park, California. The company specializes in a bio-computational platform that facilitates the extraction of insights from diverse biological samples. Its Enable Cloud Platform offers a collaborative ecosystem equipped with tools for generating, visualizing, and analyzing various biological image formats. By providing end-to-end services that include custom panel development, data acquisition through advanced imaging technology, and spatial data analysis, Enable Medicine supports researchers, drug developers, and physicians in creating cellular maps that enhance drug discovery processes. The platform aims to reduce costs and accelerate the time required to achieve scientific insights.

Tavira Therapeutics specializes in enhancing the delivery of gene therapies using adeno-associated viruses (AAV). The company's core business involves equipping AAV vectors with specific molecules to achieve targeted and safer gene therapies, thereby advancing the field of gene medicine. Established as a spin-off from KU Leuven and Trellis, Tavira leverages cutting-edge research to develop modular AAV capsid technologies, aiming to improve existing gene therapy treatments for various genetic disorders.

Pharmacelera is a biotechnology company that specializes in drug discovery by leveraging advanced computational techniques. Its platform utilizes accurate Quantum Mechanics algorithms, Machine Learning, and High-Performance Computing to explore vast and diverse chemical spaces, identifying molecular candidates with enhanced potential for drug development. The technology, rooted in over 25 years of research from the University of Barcelona, employs a 3D representation of molecules based on electrostatic, steric, and hydrophobic interaction fields derived from semi-empirical quantum mechanics calculations. This innovative approach has been validated through scientific peer-reviewed publications and benchmarking studies, providing bioinformaticians and medicinal chemists with reliable tools to accelerate their drug discovery efforts.

Constructive Bio is a biotechnology company focused on genome rewriting to advance bioprocesses and biopharmaceuticals. By transforming living cells into biofactories, it aims to develop sustainable materials and therapeutics. The company possesses the capability to create virus-resistant organisms and utilizes its proprietary technology to biosynthesize various classes of enzymes, pharmaceuticals, and biomaterials. This innovative approach allows clients to reprogram the genetic code, enabling the production of natural molecules and exploring chemical spaces that are not accessible through traditional biological methods. Constructive Bio's work positions it at the forefront of biotechnology, paving the way for the next generation of sustainable solutions in the life sciences sector.

Sestina Bio, LLC, established in 2020 and headquartered in Delaware, is a biotechnology company dedicated to addressing global challenges through innovative synthetic biology solutions. The company's mission is to create an advanced research and development platform that integrates cutting-edge technologies such as synthetic biology, data sciences, and bio-analytical systems. Sestina Bio specializes in engineering yeast and bacteria to produce chemicals and pharmaceuticals using its proprietary genome editing tools, single-cell biology techniques, and machine learning algorithms.

Switchback Systems is an early-stage startup founded in 2019 by Mary Noe, specializing in the development of a highly scalable DNA synthesis platform. The company aims to revolutionize nucleic acid applications by significantly reducing the time, cost, and waste associated with DNA synthesis. Its innovative technologies leverage cell structure as a medium for data storage, enabling the creation of a benchtop DNA printer that provides on-demand biological discovery for laboratories across the healthcare industry. Through these advancements, Switchback Systems seeks to enhance the efficiency and accessibility of genetic research and development.